Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)

Inclusion Criteria:

- Eastern Collaborative Oncology Group (ECOG) performance score of less than or equal to
2.

- Documented relapsed or progressive Multiple Myeloma (MM) on or after any regimen or is
refractory to the most recent line of therapy.

- Received prior treatment with at least 1, but no more than 3, prior lines of therapy
for MM.

- Measurable disease on Screening per International Myeloma Working Group (IMWG)
criteria.

- Meets absolute neutrophil count, platelet count, hemoglobin, liver and kidney function
laboratory values within 2 weeks prior to first dose of study drug.

- For Part 3, Cohort 7, participants must meet the above criteria and also be positive
for translocation t(11;14) as determined by an analytically validated Fluorescent In
Situ Hybridization (FISH) assay per central laboratory testing.

Exclusion Criteria:

- Has a pre-existing condition that is contraindicated including

- Non-secretory or oligo-secretory MM

- Active plasma cell leukemia

- Waldenström's macroglobulinemia

- Primary amyloidosis

- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
skin changes)

- Active hepatitis B or C infection based on screening blood testing

- Significant cardiovascular disease

- Major surgery within 4 weeks prior to first dose

- Acute infections requiring antibiotic, antifungal or antiviral therapy within14 days
prior to first dose

- Peripheral neuropathy ≥ Grade 3 or ≥ Grade 2 with pain within 2 weeks prior to first
dose

- Uncontrolled diabetes or uncontrolled hypertension within 14 days prior to first dose

- Any other medical condition that, in the opinion of the Investigator, would adversely
affect the subject's participation in the study.

- History of other active malignancies, including myelodysplastic syndrome (MDS), within
the past 3 years prior to study entry Other protocol defined inclusion/exclusion
criteria could apply